Hester Biosciences Limited reported a consolidated net profit of ₹967.32M for Q1FY27, a 459% year-on-year increase from ₹172.96M in Q1FY26. The surge was primarily driven by an exceptional accounting gain of ₹853.49M following the amendment of a loan with the Gates Foundation at its subsidiary, Hester Biosciences Africa Limited (HBAL). While headline profits soared, core operational metrics showed mixed results, with standalone revenue rising 14% to ₹726.60M while consolidated revenue declined 8% due to lower contributions from Nepal and Africa operations. Management attributed the strong standalone performance to robust execution in the Poultry Healthcare division and improved gross margins.

Operational Drivers and Segment Performance

On a standalone basis, the Poultry Healthcare division delivered a robust 48% revenue growth to ₹617.69M, driven by higher institutional business, deeper market penetration, and the early traction of new feed supplements and disinfectant solutions. Executive Director Priya Gandhi noted that the company is positioning vaccination as part of a holistic disease prevention approach, combining vaccines with biosecurity and gut health products. This strategy has strengthened customer engagement without relying on price increases. In contrast, the Animal Healthcare division experienced a 50% revenue decline to ₹108.44M, which Chief Executive Officer Rajiv Gandhi clarified was due to delays in government-led immunisation programme tender executions rather than any underlying demand shift.

Standalone net profit after tax (PAT) rose sharply by 88% to ₹147.11M from ₹78.38M. Standalone EBITDA expanded by 95% to ₹260.34M, with margins improving to 36% from 21% in the prior year quarter. Gross profit margins also widened to 78% from 69%, supported by a favourable product mix and operational efficiencies.

International Operations and Capacity Utilization

Consolidated revenues were lower largely due to variability in institutional order timing in Nepal and ongoing market development efforts in Africa. The outstanding principal of the HBAL loan was reduced from USD 12.00 million to USD 5.00 million, with all accrued interest waived and the revised loan made interest-free. CFO Ashish Desai disclosed that consolidated debt stood at ₹103 crore as of June 30, 2026, and confirmed that the Africa entity retains tax-free status until 2030. Management described the Africa operation as being in a "formative period" rather than a standard gestation phase, citing geopolitical and financial challenges in the region but maintaining confidence in long-term opportunities.

Regarding manufacturing capabilities, Rajiv Gandhi stated that overall plant capacity utilization is approximately 60% to 65%, including the recently commissioned BSL3 facility and fill-and-finish lines. The company is repurposing its BSL3 infrastructure for veterinary products, aiming for optimum utility over time. While specific capacity figures for the new facilities were not disclosed, management emphasized that the infrastructure supports future pipeline products in biologicals.

What the Numbers Show

The financial results underscore a bifurcated performance narrative for Hester Biosciences. Operationally, the company is executing well in its core domestic poultry business, with significant margin expansion and revenue growth driven by market share gains rather than pricing power. However, the reliance on government tenders in animal healthcare and volatile international markets continues to pose challenges. The massive exceptional gain masks a decline in underlying pre-tax profitability at the consolidated level, suggesting that while the balance sheet has been strengthened through debt relief, operational cash generation remains sensitive to external regulatory and market timing factors. The divergence between standalone strength and consolidated weakness highlights the continued drag from international segments, which management views as long-term strategic investments rather than near-term profit centers.

Source: https://lodr-files.dhan.co/lodr-inputs/Company/INE782E01017/92fd0a75-1400-451e-a0ab-c85ebfb9c60b.pdf

Hester Biosciences Limited has launched a dedicated interactive microsite to present its 39th Annual Report for the financial year 2025-26. The move aims to enhance accessibility for investors and stakeholders while aligning with the company’s broader objectives of digital transformation and sustainable communication practices. The filing was submitted to the Bombay Stock Exchange and the National Stock Exchange of India Limited on July 31, 2027.

The digital platform replaces traditional static formats with a user-friendly interface designed for seamless navigation across devices. Key features include an interactive presentation of financial, operational, and strategic highlights, along with convenient options for downloading and sharing the report. Vinod Mali, Company Secretary & Compliance Officer, confirmed the launch in a submission dated July 31, 2027, noting that the initiative reflects the company’s commitment to stakeholder-centred engagement.

Digital Transformation Initiative

The microsite is accessible at https://annualreport.hester.in/ and serves as part of Hester Biosciences’ ongoing efforts to modernize investor relations. By digitizing the annual report, the company seeks to reduce paper usage and promote environmentally sustainable practices. The platform allows users to explore key metrics and strategic updates through an intuitive layout, improving the overall user experience compared to previous physical or PDF-based distributions.

Key Features

This initiative follows the company’s earlier submission of the 39th Annual Report on June 18, 2026. The digital format ensures that stakeholders can access critical information regarding the company’s performance in FY 2025-26 more efficiently. The move underscores Hester Biosciences’ focus on leveraging technology to improve transparency and engagement with its investor base.